Report of erm(B)⁺ Campylobacter jejuni in the United States

Antimicrob Agents Chemother. 2018 May 25;62(6):e02615-17. doi: 10.1128/AAC.02615-17. Print 2018 Jun.

Authors

Jessica C Chen¹, Kaitlin A Tagg², Yoo Jin Joung³, Christy Bennett², Louise Francois Watkins⁴, Dana Eikmeier⁵, Jason P Folster⁴

Affiliations

¹ IHRC Inc., Atlanta, Georgia, USA lly3@cdc.gov.
² IHRC Inc., Atlanta, Georgia, USA.
³ Oak Ridge Institute for Science and Education, Knoxville, Tennessee, USA.
⁴ Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
⁵ Minnesota Department of Health, St. Paul, Minnesota, USA.

No abstract available

Keywords: Campylobacter; antimicrobial resistance; erm(B),; macrolides; whole-genome sequencing.

Publication types

Letter

MeSH terms

Anti-Bacterial Agents
Campylobacter Infections / drug therapy
Campylobacter Infections / microbiology
Campylobacter jejuni / drug effects
Campylobacter jejuni / genetics
Campylobacter jejuni / metabolism*
Campylobacter jejuni / pathogenicity*
Drug Resistance, Bacterial / genetics
Humans
Macrolides / therapeutic use
Microbial Sensitivity Tests
United States

Substances

Anti-Bacterial Agents
Macrolides